Abbisko Cayman Reports Positive Phase II Results for Oral PD-L1 Inhibitor ABSK043 in NSCLC Combination Therapy
Reuters
Dec 08
Abbisko Cayman Reports Positive Phase II Results for Oral PD-L1 Inhibitor ABSK043 in NSCLC Combination Therapy
Abbisko Cayman Limited announced the preliminary results from the dose escalation phase of its ongoing Phase II clinical study evaluating the oral small-molecule PD-L1 inhibitor ABSK043 in combination with the third-generation EGFR-TKI, firmonertinib, for the treatment of non-small cell lung cancer (NSCLC). The data, presented at the European Society for Medical Oncology Asia Congress 2025 (ESMO Asia 2025), indicated that the combination therapy demonstrated favorable safety and tolerability. Regulatory authorities have agreed to expand the program into a first-line study in treatment-naïve patients with EGFR mutated, PD-L1 positive NSCLC. Abbisko Cayman Limited noted that there is no guarantee that ABSK043 will ultimately be successfully marketed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbisko Cayman Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251208-11947313), on December 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.